Literature DB >> 23240585

Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome.

Leah R Villegas1, Dylan Kluck, Carlie Field, Rebecca E Oberley-Deegan, Crystal Woods, Michael E Yeager, Karim C El Kasmi, Rashmin C Savani, Russell P Bowler, Eva Nozik-Grayck.   

Abstract

AIMS: Pulmonary hypertension (PH) is characterized by an oxidant/antioxidant imbalance that promotes abnormal vascular responses. Reactive oxygen species, such as superoxide (O(2)(•-)), contribute to the pathogenesis of PH and vascular responses, including vascular remodeling and inflammation. This study sought to investigate the protective role of a pharmacological catalytic antioxidant, a superoxide dismutase (SOD) mimetic (MnTE-2-PyP), in hypoxia-induced PH, vascular remodeling, and NALP3 (NACHT, LRR, and PYD domain-containing protein 3)-mediated inflammation.
RESULTS: Mice (C57/BL6) were exposed to hypobaric hypoxic conditions, while subcutaneous injections of MnTE-2-PyP (5 mg/kg) or phosphate-buffered saline (PBS) were given 3× weekly for up to 35 days. SOD mimetic-treated groups demonstrated protection against increased right ventricular systolic pressure, indirect measurements of pulmonary artery pressure, and RV hypertrophy. Vascular remodeling was assessed by Ki67 staining to detect vascular cell proliferation, α-smooth muscle actin staining to analyze small vessel muscularization, and hyaluronan (HA) measurements to assess extracellular matrix modulation. Activation of the NALP3 inflammasome pathway was measured by NALP3 expression, caspase-1 activation, and interleukin 1-beta (IL-1β) and IL-18 production. Hypoxic exposure increased PH, vascular remodeling, and NALP3 inflammasome activation in PBS-treated mice, while mice treated with MnTE-2-PyP showed an attenuation in each of these endpoints. INNOVATION: This study is the first to demonstrate activation of the NALP3 inflammasome with cleavage of caspase-1 and release of active IL-1 β and IL-18 in chronic hypoxic PH, as well as its attenuation by the SOD mimetic, MnTE-2-PyP.
CONCLUSION: The ability of the SOD mimetic to scavenge extracellular O(2)(•-) supports our previous observations in EC-SOD-overexpressing mice that implicate extracellular oxidant/antioxidant imbalance in hypoxic PH and implicates its role in hypoxia-induced inflammation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23240585      PMCID: PMC3619229          DOI: 10.1089/ars.2012.4799

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  50 in total

Review 1.  Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis.

Authors:  Corrine R Kliment; Tim D Oury
Journal:  Free Radic Biol Med       Date:  2010-05-07       Impact factor: 7.376

2.  Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats.

Authors:  M Rashid; A Kotwani; M Fahim
Journal:  Hum Exp Toxicol       Date:  2011-12-05       Impact factor: 2.903

3.  Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension.

Authors:  Eleni Vergadi; Mun Seog Chang; Changjin Lee; Olin D Liang; Xianlan Liu; Angeles Fernandez-Gonzalez; S Alex Mitsialis; Stella Kourembanas
Journal:  Circulation       Date:  2011-04-25       Impact factor: 29.690

4.  Exacerbated pulmonary arterial hypertension and right ventricular hypertrophy in animals with loss of function of extracellular superoxide dismutase.

Authors:  Dachun Xu; Haipeng Guo; Xin Xu; Zhongbing Lu; John Fassett; Xinli Hu; Yawei Xu; Qizhu Tang; Dayi Hu; Arif Somani; Aron M Geurts; Eric Ostertag; Robert J Bache; E Kenneth Weir; Yingjie Chen
Journal:  Hypertension       Date:  2011-07-05       Impact factor: 10.190

5.  A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced lung injury in vivo.

Authors:  B J Day; J D Crapo
Journal:  Toxicol Appl Pharmacol       Date:  1996-09       Impact factor: 4.219

Review 6.  NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production?

Authors:  Jurg Tschopp; Kate Schroder
Journal:  Nat Rev Immunol       Date:  2010-02-19       Impact factor: 53.106

7.  Hypoxia-induced IL-18 increases hypoxia-inducible factor-1alpha expression through a Rac1-dependent NF-kappaB pathway.

Authors:  Jeongki Kim; Yan Shao; Sang Yong Kim; Seyl Kim; Hyun Keun Song; Jun Ho Jeon; Hyun Woo Suh; Jin Woong Chung; Suk Ran Yoon; Young Sang Kim; Inpyo Choi
Journal:  Mol Biol Cell       Date:  2007-11-14       Impact factor: 4.138

8.  Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice.

Authors:  Tomoaki Hoshino; Masaki Okamoto; Yuki Sakazaki; Seiya Kato; Howard A Young; Hisamichi Aizawa
Journal:  Am J Respir Cell Mol Biol       Date:  2009-03-05       Impact factor: 6.914

9.  Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats.

Authors:  Fumihiko Kamezaki; Hiromi Tasaki; Kazuhito Yamashita; Masato Tsutsui; Shinichiro Koide; Sei Nakata; Akihide Tanimoto; Masahiro Okazaki; Yasuyuki Sasaguri; Tetsuo Adachi; Yutaka Otsuji
Journal:  Am J Respir Crit Care Med       Date:  2007-10-25       Impact factor: 21.405

10.  High levels of hyaluronan in idiopathic pulmonary arterial hypertension.

Authors:  Metin Aytekin; Suzy A A Comhair; Carol de la Motte; Sudip K Bandyopadhyay; Carol F Farver; Vincent C Hascall; Serpil C Erzurum; Raed A Dweik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-09-05       Impact factor: 5.464

View more
  30 in total

1.  Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling.

Authors:  Jahidur Rashid; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-11       Impact factor: 5.464

Review 2.  Inflammasomes: a novel therapeutic target in pulmonary hypertension?

Authors:  Tara Elizabeth Scott; Barbara K Kemp-Harper; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2018-06-27       Impact factor: 8.739

3.  Caspase-1 Plays a Critical Role in Accelerating Chronic Kidney Disease-Promoted Neointimal Hyperplasia in the Carotid Artery.

Authors:  Lucas M Ferrer; Alexandra M Monroy; Jahaira Lopez-Pastrana; Gayani Nanayakkara; Ramon Cueto; Ya-Feng Li; Xinyuan Li; Hong Wang; Xiao-Feng Yang; Eric T Choi
Journal:  J Cardiovasc Transl Res       Date:  2016-02-29       Impact factor: 4.132

Review 4.  Inflammasomes link vascular disease with neuroinflammation and brain disorders.

Authors:  Nikolett Lénárt; David Brough; Ádám Dénes
Journal:  J Cereb Blood Flow Metab       Date:  2016-08-02       Impact factor: 6.200

Review 5.  Role of reactive oxygen species in neonatal pulmonary vascular disease.

Authors:  Stephen Wedgwood; Robin H Steinhorn
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

6.  Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Authors:  Victor Tseng; Roy L Sutliff; C Michael Hart
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

Review 7.  Inflammation and hypertension: new understandings and potential therapeutic targets.

Authors:  Carmen De Miguel; Nathan P Rudemiller; Justine M Abais; David L Mattson
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

Review 8.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

9.  Antioxidant therapy for the treatment of pulmonary hypertension.

Authors:  Yuichiro J Suzuki; Robin H Steinhorn; Mark T Gladwin
Journal:  Antioxid Redox Signal       Date:  2013-02-28       Impact factor: 8.401

10.  A common polymorphism in extracellular superoxide dismutase affects cardiopulmonary disease risk by altering protein distribution.

Authors:  John M Hartney; Timothy Stidham; David A Goldstrohm; Rebecca E Oberley-Deegan; Michael R Weaver; Zuzana Valnickova-Hansen; Carsten Scavenius; Richard K P Benninger; Katelyn F Leahy; Richard Johnson; Fabienne Gally; Beata Kosmider; Angela K Zimmermann; Jan J Enghild; Eva Nozik-Grayck; Russell P Bowler
Journal:  Circ Cardiovasc Genet       Date:  2014-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.